Thu, Jul 24, 2014, 7:54 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Amarin Corporation plc Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • mtdsus mtdsus Oct 5, 2012 2:55 PM Flag

    LARGE CO.can do it better-MYTH---- Small far better.

    AJAX--you are right that are doing most of the innovations.But failure rate of high also because of Risks. DNDN,SVNT are one of those co.
    GILD,MDVN ,REGN are the success stories.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Not exactly: Most Biotech failures, 95% are due to safety issues in late stage clinical trials.
      That said, I was short DNDN. HGSI, and SVNT. The reasoning was that all three products were flawed. Marketing a new drug regardless of the exciting benefits of Vascepa, is the
      most difficult task. A non vertically integrated Biotch Co. launching a new drug.for the first
      time is the most challenging of all potential pitfalls.

      Sentiment: Strong Buy

      • 1 Reply to ajax133
      • Ajax
        I enjoy reading your posts .
        I would just pt out that Vascepa has to be one of the safest drugs ever to launch.
        There appear to be no safety issues other then if the person is allergic to fish or has a bleeding issue.
        In addition's going thru the door opened by Lovaza. Those that I know that prescribe drugs look at Vascepa and say " ok it's Lovaza WITHOUT the LDL cholesterol problem won't hurt you , may help you "
        Now we know it's more then that but that's the quick take away from those I know who prescribe drugs .
        In addition there is a huge unmet medical need I would like to know why you think Vascepa
        may be a difficult launch .....I think the opposite

        Sentiment: Buy

1.57-0.01(-0.63%)Jul 24 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.